Expert Group of Consensus on Treating Infantile Hemangiomas with Atenolol.Chinese Expert Consensus on Using Oral Atenolol for Infantile Hemangiomas[J].Journal of Clinical Pediatric Surgery,2023,22(04):301-306.[doi:10.3760/cma.j.cn101785-202207052-001]
口服阿替洛尔治疗婴幼儿血管瘤的中国专家共识(2023年版)
- Title:
- Chinese Expert Consensus on Using Oral Atenolol for Infantile Hemangiomas
- 摘要:
- 非选择性β受体阻滞剂普萘洛尔作为用于婴幼儿血管瘤治疗的一线药物具有较好的疗效,但其可能存在气道高反应性、低血糖以及中枢神经系统潜在影响的药物不良反应。近年来,选择性β1受体阻滞剂阿替洛尔作为普萘洛尔治疗婴幼儿血管瘤的替代药物,在临床上的应用越来越多。为了规范阿替洛尔在婴幼儿血管瘤中的应用,指导临床安全、科学、合理用药,本共识经国内多名不同专业具有丰富婴幼儿血管瘤诊疗经验的专家共同讨论,形成阿替洛尔治疗婴幼儿血管瘤的中国专家共识,旨在为临床提供指导和参考。
参考文献/References:
[1] Léauté-Labrèze C,Harper JI,Hoeger PH.Infantile haemangioma[J].Lancet,2017,390(10089):85-94.DOI:10.1016/S0140-6736(16)00645-0.
[2] Anderson KR,Schoch JJ,Lohse CM,et al.Increasing incidence of infantile hemangiomas (IH) over the past 35 years:correlation with decreasing gestational age at birth and birth weight[J].J Am Acad Dermatol,2016,74(1):120-126.DOI:10.1016/j.jaad.2015.08.024.
[3] Ding Y,Zhang JZ,Yu SR,et al.Risk factors for infantile hemangioma:a meta-analysis[J].World J Pediatr,2020,16(4):377-384.DOI:10.1007/s12519-019-00327-2.
[4] Drolet BA,Swanson EA,Frieden IJ,et al.Infantile hemangiomas:an emerging health issue linked to an increased rate of low birth weight infants[J].J Pediatr,2008,153(5):712-715.e1.DOI:10.1016/j.jpeds.2008.05.043.
[5] Krowchuk DP,Frieden IJ,Mancini AJ,et al.Clinical practice guideline for the management of infantile hemangiomas[J].Pediatrics,2019,143(1):e20183475.DOI:10.1542/peds.2018-3475.
[6] Darrow DH,Greene AK,Mancini AJ,et al.Diagnosis and management of infantile hemangioma[J].Pediatrics,2015,136(4):e1060-e1104.DOI:10.1542/peds.2015-2485.
[7] Tollefson MM,Frieden IJ.Early growth of infantile hemangiomas:what parents’ photographs tell us[J].Pediatrics,2012,130(2):e314-e320.DOI:10.1542/peds.2011-3683.
[8] Léauté-Labrèze C,Baselga Torres E,Weibel L,et al.The infantile hemangioma referral score:a validated Tool for physicians[J].Pediatrics,2020,145(4):e20191628.DOI:10.1542/peds.2019-1628.
[9] Léauté-Labrèze C,Dumas de la Roque E,Hubiche T,et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med,2008,358(24):2649-2651.DOI:10.1056/NEJMc0708819.
[10] Léauté-Labrèze C,Hoeger P,Mazereeuw-Hautier J,et al.A randomized,controlled trial of oral propranolol in infantile hemangioma[J].N Engl J Med,2015,372(8):735-746.DOI:10.1056/NEJMoa1404710.
[11] Marqueling AL,Oza V,Frieden IJ,et al.Propranolol and infantile hemangiomas four years later:a systematic review[J].Pediatr Dermatol,2013,30(2):182-191.DOI:10.1111/pde.12089.
[12] Itinteang T,Marsh R,Davis PF,et al.Angiotensin Ⅱ causes cellular proliferation in infantile haemangioma via angiotensin Ⅱ receptor 2 activation[J].J Clin Pathol,2015,68(5):346-350.DOI:10.1136/jclinpath-2014-202794.
[13] Itinteang T,Brasch HD,Tan ST,et al.Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution[J].J Plast Reconstr Aesthet Surg,2011,64(6):759-765.DOI:10.1016/j.bjps.2010.08.039.
[14] van Schaijik B,Tan ST,Marsh RW,et al.Expression of (pro)renin receptor and its effect on endothelial cell proliferation in infantile hemangioma[J].Pediatr Res,2019,86(2):202-207.DOI:10.1038/s41390-019-0430-8.
[15] Itinteang T,Withers AHJ,Davis PF,et al.Biology of infantile hemangioma[J].Front Surg,2014,1:38.DOI:10.3389/fsurg.2014.00038.
[16] Storch CH,Hoeger PH.Propranolol for infantile haemangiomas:insights into the molecular mechanisms of action[J].Br J Dermatol,2010,163(2):269-274.DOI:10.1111/j.1365-2133.2010.09848.x.
[17] Léaute-Labrèze C,Boccara O,Degrugillier-Chopinet C,et al.Safety of oral propranolol for the treatment of infantile hemangioma:a systematic review[J].Pediatrics,2016,138(4):e20160353.DOI:10.1542/peds.2016-0353.
[18] Pope E.Commentary:beta-blockers and sleep problems[J].Pediatr Dermatol,2021,38(2):378-379.DOI:10.1111/pde.14537.
[19] Wang Q,Xiang B,Chen SY,et al.Efficacy and safety of oral atenolol for the treatment of infantile haemangioma:a systematic review[J].Australas J Dermatol,2019,60(3):181-185.DOI:10.1111/ajd.12966.
[20] Ji Y,Chen SY,Wang Q,et al.Intolerable side effects during propranolol therapy for infantile hemangioma:frequency,risk factors and management[J].Sci Rep,2018,8(1):4264.DOI:10.1038/s41598-018-22787-8.
[21] Hoeger PH,Harper JI,Baselga E,et al.Treatment of infantile haemangiomas:recommendations of a European expert group[J].Eur J Pediatr,2015,174(7):855-865.DOI:10.1007/s00431-015-2570-0.
[22] ábarzúa-Araya A,Navarrete-Dechent CP,Heusser F,et al.Atenolol versus propranolol for the treatment of infantile hemangiomas:a randomized controlled study[J].J Am Acad Dermatol,2014,70(6):1045-1049.DOI:10.1016/j.jaad.2014.01.905.
[23] Gumina ME,Yan AC.Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas[J].Pediatr Dermatol,2019,36(4):556-557.DOI:10.1111/pde.13839.
[24] 王琦,向波,吉毅,等.普萘洛尔与阿替洛尔治疗婴儿血管瘤的比较研究[J].中华皮肤科杂志,2016,49(10):683-687.DOI:10.3760/cma.j.issn.0412-4030.2016.10.001. Wang Q,Xiang B,Ji Y,et al.Propranolol versus atenolol in the treatment of infantile hemangioma:a comparative study[J].Chin J Dermatol,2016,49(10):683-687.DOI:10.3760/cma.j.issn.0412-4030.2016.10.001.
[25] Kirch W,G?rg KG.Clinical pharmacokinetics of atenolol-a review[J].Eur J Drug Metab Pharmacokinet,1982,7(2):81-91.DOI:10.1007/BF03188723.
[26] Zhou HH,Koshakji RP,Silberstein DJ,et al.Racial differences in drug response.Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites[J].N Engl J Med,1989,320(9):565-570.DOI:10.1056/NEJM198903023200905.
[27] Ji Y,Chen SY,Yang KY,et al.Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas:a randomized clinical trial[J].JAMA Otolaryngol Head Neck Surg,2021,147(7):599-607.DOI:10.1001/jamaoto.2021.0454.
[28] Dakoutrou M,Alexopoulos A,Miligkos M,et al.Atenolol treatment for severe infantile hemangiomas:comparison with a propranolol group of our centre[J].J Eur Acad Dermatol Venereol,2019,33(5):e199-e200.DOI:10.1111/jdv.15464.
[29] Bayart CB,Tamburro JE,Vidimos AT,et al.Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase:a retrospective noninferiority study[J].Pediatr Dermatol,2017,34(4):413-421.DOI:10.1111/pde.13177.
[30] de Graaf M,Raphael MF,Breugem CC,et al.Treatment of infantile haemangiomas with atenolol:comparison with a historical propranolol group[J].J Plast Reconstr Aesthet Surg,2013,66(12):1732-1740.DOI:10.1016/j.bjps.2013.07.035.
[31] Zhao ZL,Liu C,Wang QZ,et al.Oral atenolol treatment for infantile hemangiomas:clinical analysis of 133 consecutive patients[J].Ann Transl Med,2021,9(2):116.DOI:10.21037/atm-20-5359.
[32] Chen T,Gudipudi R,Nguyen SA,et al.Should propranolol remain the gold standard for treatment of infantile hemangioma? A systematic review and meta-analysis of propranolol versus atenolol[J].Ann Otol Rhinol Laryngol,2023,132(3):332-340.DOI:10.1177/00034894221089758.
[33] 郑健敏,朱智胜,王朝阳,等.口服阿替洛尔对比口服普萘洛尔治疗婴幼儿血管瘤疗效及安全性的meta分析[J].中华整形外科杂志,2022,38(3):275-283.DOI:10.3760/cma.j.cn114453-20210927-00394. Zheng JM,Zhu ZS,Wang CY,et al.Meta-analysis of efficacy and safety of oral atenolol versus oral propranolol in the treatment of infantile hemangioma[J].Chin J Plast Surg,2022,38(3):275-283.DOI:10.3760/cma.j.cn114453-20210927-00394.
[34] Ji Y,Wang Q,Chen SY,et al.Oral atenolol therapy for proliferating infantile hemangioma:a prospective study[J].Medicine (Baltimore),2016,95(24):e3908.DOI:10.1097/MD.0000000000003908.
[35] Alexopoulos A,Thanopoulou I,Dakoutrou M,et al.Atenolol treatment for severe infantile hemangiomas:a single-centre prospective study[J].J Eur Acad Dermatol Venereol,2018,32(3):e117-e119.DOI:10.1111/jdv.14590.
[36] Ruitenberg G,Young-Afat DA,de Graaf M,et al.Ulcerated infantile haemangiomas:the effect of the selective beta-blocker atenolol on wound healing[J].Br J Dermatol,2016,175(6):1357-1360.DOI:10.1111/bjd.14687.
相似文献/References:
[1]王涛,刘昌荣,邓立才,等.不同β受体阻滞剂治疗婴幼儿血管瘤的疗效观察[J].临床小儿外科杂志,2024,(02):168.[doi:10.3760/cma.j.cn101785-202208021-013]
Wang Tao,Liu Changrong,Deng Licai,et al.Clinical efficacies of different types of β receptor blockers for infantile hemangioma[J].Journal of Clinical Pediatric Surgery,2024,(04):168.[doi:10.3760/cma.j.cn101785-202208021-013]
备注/Memo
收稿日期:2022-7-27。
基金项目:国家自然科学基金(82273556);四川省科技厅重点研发项目(2022YFS0233、2022YFS0225、2022NSFSC1480);四川大学"从0到1创新项目"(2022SCUH0033);四川大学医学+信息中心交叉学科建设开放项目(YGJC004);四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目(2019HXFH056、2020HXFH048);四川大学华西医院学科卓越发展1·3·5工程交叉学科创新项目(ZYJC21060)
通讯作者:郑家伟,Email:davidzhengjw@situ.edu.en;吉毅,Email:jijiyuanyuan@163.com